Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis.

ABSTRACT:

Background

The efficacy of efgartigimod in treating myasthenia gravis (MG) patients with muscle-specific kinase (MuSK) antibodies has not been demonstrated in the clinical trial, existing case reports, or observational studies.

Objectives

To evaluate the efficacy and safety of efgartigimod combined with immunotherapies such as tacrolimus or B-cell depleting agents, as maintenance treatment for MuSK-MG patients.

Design

This retrospective study included 14 MuSK-MG patients treated with efgartigimod at three tertiary hospitals from 2023 to 2024.

Methods

Data on the activities of daily living (ADL) scores, Quantitative Myasthenia Gravis scores, and the time reaching minimal symptom expression (MSE) were collected. The combined use of steroids, immunosuppressants, a

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC11938440 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature